(1R,2R,3S,5S)-2-((6-(benzyloxy)-6-oxohexyl)carbamoyl)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate trifluoroacetate salt | 1431753-53-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R,2R,3S,5S)-2-((6-(benzyloxy)-6-oxohexyl)carbamoyl)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate trifluoroacetate salt
• 英文别名: [(1R,2R,3S,5S)-8-methyl-2-[(6-oxo-6-phenylmethoxyhexyl)carbamoyl]-8-azabicyclo[3.2.1]octan-3-yl] benzoate;2,2,2-trifluoroacetic acid
• CAS: 1431753-53-5
• 化学式: C₂HF₃O₂*C₂₉H₃₆N₂O₅
• 分子量: 606.639
• InChiKey: JOBMXKHXBZLISK-LVMITRCISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.75
• 重原子数：
  43
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  122
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  (1R,2R,3S,5S)-2-((6-(benzyloxy)-6-oxohexyl)carbamoyl)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate trifluoroacetate salt 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 以60%的产率得到6-((1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxamido)hexanoic acid trifluoroacetate salt
  参考文献：
  名称：

  Probing Active Cocaine Vaccination Performance through Catalytic and Noncatalytic Hapten Design

  摘要：

  Presently, there are no FDA-approved medications to treat cocaine addiction. Active vaccination has emerged as one approach to intervene through the rapid sequestering of the circulating drug, thus terminating both psychoactive effects and drug toxicity. Herein, we report our efforts examining two complementary, but mechanistically distinct active vaccines, i.e., noncatalytic and catalytic, for cocaine treatment. A cocaine-like hapten GNE and a cocaine transition-state analogue GNT were used to generate the active vaccines, respectively. GNE-KLH (keyhole limpet hemocyannin) was found to elicit persistent high-titer, cocaine-specific antibodies and blunt cocaine-induced locomotor behaviors. Catalytic antibodies induced by GNT-KLH were also shown to produce potent titers and suppress locomotor response in mice; however, upon repeated cocaine challenges, the vaccine's protecting effects waned. In depth kinetic analysis suggested that loss of catalytic activity was due to antibody modification by cocaine. The work provides new insights for the development of active vaccines for the treatment of cocaine abuse.

  DOI：

  10.1021/jm400228w
• 作为产物：
  描述：

  芽子碱 在 N-甲基吗啉 、 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.67h， 生成 (1R,2R,3S,5S)-2-((6-(benzyloxy)-6-oxohexyl)carbamoyl)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate trifluoroacetate salt
  参考文献：
  名称：

  Probing Active Cocaine Vaccination Performance through Catalytic and Noncatalytic Hapten Design

  摘要：

  Presently, there are no FDA-approved medications to treat cocaine addiction. Active vaccination has emerged as one approach to intervene through the rapid sequestering of the circulating drug, thus terminating both psychoactive effects and drug toxicity. Herein, we report our efforts examining two complementary, but mechanistically distinct active vaccines, i.e., noncatalytic and catalytic, for cocaine treatment. A cocaine-like hapten GNE and a cocaine transition-state analogue GNT were used to generate the active vaccines, respectively. GNE-KLH (keyhole limpet hemocyannin) was found to elicit persistent high-titer, cocaine-specific antibodies and blunt cocaine-induced locomotor behaviors. Catalytic antibodies induced by GNT-KLH were also shown to produce potent titers and suppress locomotor response in mice; however, upon repeated cocaine challenges, the vaccine's protecting effects waned. In depth kinetic analysis suggested that loss of catalytic activity was due to antibody modification by cocaine. The work provides new insights for the development of active vaccines for the treatment of cocaine abuse.

  DOI：

  10.1021/jm400228w